2023
Atezolizumab for Advanced Alveolar Soft Part Sarcoma
Chen A, Sharon E, O'Sullivan-Coyne G, Moore N, Foster J, Hu J, Van Tine B, Conley A, Read W, Riedel R, Burgess M, Glod J, Davis E, Merriam P, Naqash A, Fino K, Miller B, Wilsker D, Begum A, Ferry-Galow K, Deshpande H, Schwartz G, Ladle B, Okuno S, Beck J, Chen J, Takebe N, Fogli L, Rosenberger C, Parchment R, Doroshow J. Atezolizumab for Advanced Alveolar Soft Part Sarcoma. New England Journal Of Medicine 2023, 389: 911-921. PMID: 37672694, PMCID: PMC10729808, DOI: 10.1056/nejmoa2303383.Peer-Reviewed Original ResearchConceptsAdvanced alveolar soft part sarcomaAlveolar soft part sarcomaProgression-free survivalSoft part sarcomaObjective responsePart sarcomaMedian progression-free survivalTreatment-related grade 4Rare soft tissue sarcomaData cutoff dateImmune checkpoint inhibitorsPhase 2 studyResponse Evaluation CriteriaThird of patientsDuration of responseSoft tissue sarcomasYears of treatmentCheckpoint inhibitorsAdverse eventsMedian durationPartial responseComplete responseDeath-1PD-L1Pediatric patients
2009
A phase I study investigating the combination of orally bioavailable platinum and nanoparticle albumin-bound paclitaxel in advanced solid tumors
Deshpande H, Gettinger S, Rowen E, Abu-Khalaf M, Clarke J, Burns A, Kelly W. A phase I study investigating the combination of orally bioavailable platinum and nanoparticle albumin-bound paclitaxel in advanced solid tumors. Journal Of Clinical Oncology 2009, 27: e13501-e13501. DOI: 10.1200/jco.2009.27.15_suppl.e13501.Peer-Reviewed Original ResearchNanoparticle albumin-bound paclitaxelAlbumin-bound paclitaxelCohort 2Cohort 3Cohort 1Platinum agentsSolid tumorsDay 14Common severe adverse eventsGrade 3 anemiaMedian age 51Grade 4 neutropeniaStandard chemotherapy regimenAdvanced solid tumorsPhase 2 studySevere adverse eventsNeurological side effectsCycle 1Stable diseaseChemotherapy regimenDay 1 treatmentAdvanced malignanciesAdverse eventsPartial responseProgressive disease